Aytu BioPharma (NASDAQ: AYTU) is a dynamic pharmaceutical company with a growing commercial portfolio of prescription medicines addressing complex conditions, with a focus on ADHD and other pediatric illnesses. Our evolution has been driven by strategic in-licensing, acquisition-based transactions and organic product growth. As we continue on this trajectory, we’re building a therapeutic pipeline focused on rare pediatric-onset diseases. Our pipeline is highlighted by AR101/enzastaurin, a well-characterized small molecule targeting the treatment of vascular Ehlers-Danlos Syndrome (VEDS). VEDS is a rare, genetic, life-shortening disease causing catastrophic aortic events and resulting in severe morbidity and death. There are no approved treatments for VEDS. AR101/enzastaurin received Orphan Drug designation from U.S. FDA December of 2021.